Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

David A. Ehrmann to Hyperandrogenism

This is a "connection" page, showing publications David A. Ehrmann has written about Hyperandrogenism.

 
Connection Strength
 
 
 
2.710
 
  1. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 10; 37(5):467-520.
    View in: PubMed
    Score: 0.674
  2. Sam S, Ehrmann DA. Hormonal Evaluation of Hyperandrogenism in Women. JAMA. 2015 Dec 15; 314(23):2557-8.
    View in: PubMed
    Score: 0.646
  3. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antim├╝llerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012 Jul; 98(1):242-9.
    View in: PubMed
    Score: 0.502
  4. Ehrmann DA. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus. Baillieres Clin Obstet Gynaecol. 1997 Jun; 11(2):335-47.
    View in: PubMed
    Score: 0.179
  5. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995 Jun; 16(3):322-53.
    View in: PubMed
    Score: 0.156
  6. Rosenfield RL, Ehrmann DA, Littlejohn EE. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab. 2015 Apr; 100(4):1537-43.
    View in: PubMed
    Score: 0.152
  7. Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994 Dec; 79(6):1686-92.
    View in: PubMed
    Score: 0.150
  8. Dronavalli S, Ehrmann DA. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol. 2007 Mar; 50(1):244-54.
    View in: PubMed
    Score: 0.088
  9. Rosenfield RL, Barnes RB, Ehrmann DA, Toledano AY. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003 Dec; 88(12):6115; author reply 6115-6.
    View in: PubMed
    Score: 0.070
  10. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, Rosenthal IM. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994 Nov; 79(5):1328-33.
    View in: PubMed
    Score: 0.037
  11. Mortensen M, Ehrmann DA, Littlejohn E, Rosenfield RL. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009 May; 94(5):1579-86.
    View in: PubMed
    Score: 0.025
  12. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
    View in: PubMed
    Score: 0.017
  13. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF, Spielman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8573-8.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.